Published on 27/12/2025

Understanding Local MAH Obligations in Turkey

Turkey has become a focal point for pharmaceutical companies seeking to expand their market presence in emerging markets. The local Marketing Authorization Holder (MAH) plays a crucial role in the regulatory pathway for medicines and medical devices within Turkey, governed by the Turkey Medicines & Medical Devices Authority (TMMDA). This article serves as a step-by-step guide to understanding the obligations of the local MAH in Turkey, particularly in alignment with global regulatory strategies and frameworks like those established by the FDA, EMA, and MHRA.

1. Understanding the Role of the Local MAH in Turkey

The Marketing Authorization Holder (MAH) is responsible for regulatory compliance and the commercialization of pharmaceutical products in Turkey. The MAH can be either a local entity or a foreign pharmaceutical company with a presence in Turkey. In this section, we will cover the key responsibilities and obligations of the local MAH.

1.1 Regulatory Compliance

The local MAH must ensure that the products sold in Turkey comply with the regulations established by the TMMDA. This involves:

• Maintaining a valid marketing authorization for each product.
• Ensuring that all labeling and advertising material is compliant with Turkish regulations.
• Submitting periodic safety update reports (PSURs) as mandated by TMMDA guidelines.

1.2 Quality Assurance

Quality management is key in the pharmaceutical industry. The local MAH must establish effective quality assurance processes, including:

• Implementing Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP).
• Conducting internal audits and engaging in regular reviews of product quality.
• Ensuring compliance with international standards as applicable, which helps in achieving alignment with FDA, EMA, and MHRA regulations.

1.3 Pharmacovigilance

The MAH has ongoing obligations related to pharmacovigilance. This includes:

• Establishing a risk management system for the monitoring of adverse events.
• Prompt reporting of any serious adverse effects to the TMMDA and relevant stakeholders.

2. Initial Steps for Becoming a Local MAH

For foreign companies looking to establish a local MAH in Turkey, several preliminary steps should be followed. These steps are essential for smooth regulatory submissions and compliance.

2.1 Setting Up a Local Entity

Before applying for marketing authorizations, foreign pharmaceutical companies must establish a local entity. This can be accomplished through:

• Registering a branch or subsidiary in Turkey.
• Working with a local partner who can act as the MAH.

2.2 Documentation Preparation

Once the local entity is established, the next step involves gathering necessary documentation for the marketing authorization application. Key documents include:

• Product information summary and marketing strategy.
• Certificate of Good Manufacturing Practice (GMP).
• Stability study data and clinical trial results.

3. Submission Process to TMMDA

The submission of marketing authorization applications to the TMMDA is critical for achieving market access in Turkey. The process is stringent and requires detailed submissions for approval.

3.1 Preparing the Dossier

The application dossier must comply with the Turkish format and standards, adhering to the Common Technical Document (CTD) guidelines. Important sections include:

• Administrative information and proposed product labeling.
• Quality information related to drug substance and drug product.
• Preclinical and clinical data to support efficacy and safety claims.

3.2 Submission and Review Period

After preparing the complete dossier, submission to the TMMDA can take place. It is important to note that:

• The submission process includes a formal review period, during which the TMMDA assesses the application for completeness and compliance.
• Regular follow-ups may be required to address any queries stemming from the TMMDA review process.

4. Navigating Local Regulatory Challenges

Operating in Turkey’s regulatory environment can pose challenges. Here we outline common challenges faced by local MAHs and recommendations to successfully navigate them.

4.1 Understanding Local Market Dynamics

Emerging markets such as Turkey are characterized by unique market dynamics. These include:

• Varying levels of healthcare access and infrastructure that can affect market entry strategies.
• Understanding local customs and practices that influence the adoption of new pharmaceuticals.

4.2 Alignment with Global Regulations

In order to achieve a seamless alignment with regulatory frameworks such as those from the FDA, EMA, and MHRA, local MAHs should focus on:

• Implementing standardized operating procedures that align with international practices.
• Engaging with industry associations and regulatory bodies to stay abreast of evolving regulations and guidelines.

5. Continuous Compliance and Post-Market Surveillance

Once a product is approved and launched, continuous compliance and post-marketing surveillance are vital. The following discussions will highlight key aspects of ongoing obligations.

5.1 Regular Reporting Requirements

The local MAH must adhere to regular reporting requirements. These include:

• Periodic safety update reports (PSURs) that provide a review of any new safety information related to the product.
• Annual reports detailing manufacturing processes and any changes made since initial authorization.

5.2 Market Surveillance Activities

Conducting market surveillance is critical to ensuring the ongoing safety and effectiveness of pharmaceutical products. This includes:

• Engaging in active monitoring of adverse events and product performance.
• Responding promptly to any notifications from healthcare professionals regarding product concerns.

6. Conclusion and Best Practices

Understanding the obligations of a local MAH in Turkey is essential for pharmaceutical companies wishing to tap into this growing market. Effective regulatory compliance, market strategies, and quality assurance practices serve as the foundation for successful operations. Best practices include:

• Leveraging Turkey regulatory consulting services pharma to navigate local regulations effectively.
• Regular training programs to ensure all team members are up-to-date with the latest compliance requirements.
• Building strong relationships with local regulatory authorities to facilitate smoother interactions and communication.

By following these outlined steps and strategies, pharmaceutical companies can achieve greater success in navigating the complex regulatory landscape of Turkey, aligning operations with global markets while ensuring product quality and patient safety.